wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33422543-2CFE10B7-C404-4A7A-B640-C297CC3DADF1
Q33422543-2CFE10B7-C404-4A7A-B640-C297CC3DADF1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33422543-2CFE10B7-C404-4A7A-B640-C297CC3DADF1
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
P2860
Q33422543-2CFE10B7-C404-4A7A-B640-C297CC3DADF1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33422543-2CFE10B7-C404-4A7A-B640-C297CC3DADF1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b6d495113d0a9d689a6cb524f1a8cce949c05aa0
P2860
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.